Celsius Property B.V. Amsterdam(NI) – Trademark Portfolio

Entity Type: 03

Celsius Property B.V. Amsterdam(NI) holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include ALIAS, PASADA, and DOMINION. The owner is based in Schaffhausen.

Rheimweg 7

Schaffhausen 8200 , CH

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ALIAS
ALIAS
Registered 2005
PASADA
PASADA
Registered 2005
DOMINION
DOMINION
Registered 2005

Trademark Classifications

Celsius Property B.V. Amsterdam(NI)'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Celsius Property B.V. Amsterdam(NI) have?

Celsius Property B.V. Amsterdam(NI) has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.

What trademark classes does Celsius Property B.V. Amsterdam(NI) file in?

Celsius Property B.V. Amsterdam(NI) files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Celsius Property B.V. Amsterdam(NI)'s most well-known trademarks?

Celsius Property B.V. Amsterdam(NI)'s registered trademark portfolio includes well-known marks such as ALIAS, PASADA, and DOMINION. These are among 3 currently registered trademarks in the portfolio.

What is Celsius Property B.V. Amsterdam(NI)'s trademark registration success rate?

Celsius Property B.V. Amsterdam(NI) has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.